Principal
Develop epigenetic biomarkers for high-grade serous ovarian cancer for diagnosis, monitoring of residual disease, and detection of relapse using in silico and in vivo studies
Secondaires
Correlation of methylation profiles at diagnosis to FIGO stage, progression-free survival, and overall survival
Institut Paoli Calmettes
232 Boulevard Sainte Marguerite
13273 Marseille Cedex 09
D’inclusion
Patients with high-grade serous ovarian cancer at any stage
Prior enrollment in GC-Bio or CIDOC studies
FFPE tumor tissue and/or plasma samples available for DNA analyses. Cases with already isolated DNA can be enrolled.
A cohort of healthy control subjects (women with no ovarian cancer or with non-malignant ovarian tumors) will also be required.
De non inclusion
Patients not previously enrolled in GC-Bio or CIDOC or without institutional signed consent for translational research.
No biological sample (FFPE tumor tissue or plasma) available
Traitement de données mené dans l'intérêt public dans le domaine de la santé publique (article 6.1e et 9.2.j du Règlement (UE) n°2016/679)
institut paoli calmettes
Les données seront conservées pendant la durée légale en vigueur ou tant qu'elles présenteront un intérêt scientifique